Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

This study is looking for male patients aged 12 and older who have been diagnosed with severe haemophilia A and have had treatment with a factor VIII medicine for at least 150 days in the past. You also need to be on regular treatment with emicizumab for at least a month before your planned major surgery.

There are some reasons why you might not be able to join. For example, if you have another bleeding disorder that isn't haemophilia A, or if you've ever had problems with inhibitors (antibodies that stop your haemophilia medicine from working) in the past. You also can't take part if you have serious liver or kidney disease, or if you're allergic to any of the ingredients in Nuwiq. If you've already had surgery as part of this study, or if you're currently in another medical study or have taken part in one very recently, you wouldn't be able to join this one.

If you decide to take part in this study, you would first have a screening visit to make sure you're eligible. Once accepted, you would receive Nuwiq alongside your regular emicizumab treatment, specifically timed for your major surgery. This would involve getting Nuwiq infusions before, during, and after your operation, as decided by your medical team. You would have regular check-ups by the study team, who would monitor your bleeding, your recovery from surgery, and look for any side effects. These check-ups would involve blood tests and physical examinations. The total duration of your participation would depend on your surgical recovery and follow-up plan, but the main focus is around the time of your surgery and the immediate recovery period.